Epithelial tumors of the parotid gland comprise 3% of head and neck tumors, and 70%-80% of those are benign. Pleomorphic adenoma is the most common tumor of the parotid gland. Recurrence rate of pleomorphic adenomas (RPAs) following superficial parotidectomy was reported to be as high as 4%, sometimes associated with inadequate surgical treatment of the primary tumor. These tumors have a very slow growth rate, and a ten-year follow-up period is mandatory. RPAs are usually located in the superficial lobe (75%) and are often multinodular. Treatment of RPAs is challenging due to a high risk of facial nerve paresis (7%-50%) and of re-recurrence. Occasionally, post-operative radiotherapy is indicated, but this treatment must be balanced with potential long term risks of secondary malignancy. Medical records of 16 patients with first recurrence and 4 patients with more than one recurrence who were treated in our institution during the past 5 years were reviewed. Five patients were treated by post-operative radiotherapy. Residual or recurrence rate following a second procedure was 15%. Two patients (10%) had permanent paresis of a single branch of the facial nerve. Seventeen out of 20 patients (85%) treated were disease-free after a follow-up period of 5 years. In conclusion, surgical treatment of RPAs is a complex procedure which should be managed by a trained surgical team and can be performed with success and minimal morbidity.
Download full-text PDF |
Source |
---|
Mol Clin Oncol
March 2025
Department of Pathology, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka 569-8686, Japan.
Pleomorphic adenoma (PA) is the most common salivary gland tumour. Pre-operative fine-needle aspiration (FNA) is currently one of the most widely used cytological examination techniques for the diagnosis of salivary gland tumours. Because PA exhibits characteristic cytological features, cytological diagnosis is straightforward in most cases.
View Article and Find Full Text PDFEar Nose Throat J
January 2025
Department of Neurosurgery, Christian Medical College, Vellore, TN, India.
Metastasizing pleomorphic adenoma is a rare entity that has the propensity for distant metastasis despite being histologically benign. We report the case of a 56-year-old woman with a long-standing right upper neck swelling and a recent-onset swelling over the left side of the scalp. Clinical workup did not reveal any other tumor deposits in the body.
View Article and Find Full Text PDFCureus
December 2024
Department of Diagnostic Pathology, Miyazaki Prefectural Miyazaki Hospital, Miyazaki, JPN.
Pleomorphic adenoma of the trachea is a rare benign tumor, often challenging to diagnose due to nonspecific symptoms. We report a case of a 72-year-old female with a 10-year history of presumed bronchial asthma, presenting with persistent dyspnea. Preoperative assessment for breast cancer surgery revealed severe obstructive ventilatory impairment.
View Article and Find Full Text PDFInt J Surg Case Rep
January 2025
Oral and Maxillofacial surgery Unit, Department of Dental and Maxillofacial Surgery, St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia.
Introduction: Pleomorphic adenoma, the most common benign salivary gland tumor, typically occurs in the parotid region but can also arise in minor salivary glands. Its occurrence in the lateral tongue is infrequent, making this case the first reported from Ethiopia and the second in English literature.
Case Presentation: We present an 11-year-old girl who underwent an excisional biopsy for a tongue swelling lasting 2 years.
Medicina (Kaunas)
December 2024
ENT Department, Carol Davila University of Medicine and Pharmacy, 050751 Bucharest, Romania.
: Carcinoma ex-pleiomorphic adenoma (CXPA) is a carcinoma derived from a primary or recurrent pleiomorphic adenoma. Microscopically, non-invasive CXPA (intracapsular and carcinoma in situ), minimally invasive CXPA (extracapsular invasion less than 1.5 mm), and invasive CXPA (extracapsular invasion more than 1.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!